Micromedex

What is Micromedex and who sells it?

Merative sells Micromedex from Ann Arbor, Michigan, and Francisco Partners owns Merative. The product's lineage runs from Thomson Healthcare to Truven Health Analytics, which Thomson Reuters sold to Veritas Capital in 2012, then to IBM in 2016 as part of Watson Health, and then to Francisco Partners, with Merative launching on 30 June 2022 (Wikipedia).

What does it contain?

The vendor lists more than 2,500 drug monographs with dosing and off-label uses, more than 700 clinical calculators, interaction checking, IV compatibility, and toxicology content covering more than 470,000 products, including Poisindex. RED BOOK pricing covers more than 360,000 items. There is also formulary status, NeoFax and pediatric content, alternative medicine, and more than 3,000 patient education titles in up to 15 languages. These counts are the vendor's.

The AI-powered search, released on 23 September 2025, takes natural-language questions on interactions, IV compatibility, toxicology and dosing and returns cited answers. Merative says it was validated through internal testing, external clinician validation and real-world testing, and it gives no independent accuracy data. Press coverage from 2026 names Perplexity as a premium-source partner and EBSCO Dyna AI as a content partner. The core database is editorial content, and the generative layer sits on top of it.

What about KLAS and compliance?

The vendor reports a number 1 rating in the 2026 Best in KLAS category for point-of-care drug reference, for the second time, and use in more than 80 countries. Those are claims from the product page. Desktop, mobile and EHR integration are advertised without an EHR list. The vendor lists no HIPAA, SOC 2 or HITRUST attestation, and Micromedex is not an FDA-cleared device.

What does the evidence say?

Papers that mention Micromedex mostly use it as a reference standard. A 2026 Research in Social and Administrative Pharmacy paper (PMID 41402170) used it as the comparator when assessing AI-based drug information in Thai mobile apps. A 2025 Drug Design, Development and Therapy paper (PMID 40896200) examined discordance in drug-drug interaction alerts for antidotes across databases. No independent accuracy study of the AI search exists.

SelectHub reviewers praise the interface and search but complain about slower navigation, clunky search and few clinical calculators, from a small sample on a trade review site. A rival vendor, prescriber.io, calls Micromedex "effectively institutional-only" and stronger than UpToDate for drug facts, toxicology and IV compatibility. That comparison comes from a company that sells a competing product.

How much does Micromedex cost?

Micromedex is quoted per organisation, and SelectHub lists it as a custom annual quote (as of October 2026). Library guides say the mobile apps come with an institutional subscription. A 2014 report mentioned a $2.99 app subscription and a 2016 library review listed per-app prices, but both are a decade old. The vendor offers no trial or refund terms.

How does it compare?

Lexidrug from Wolters Kluwer, UpToDate, Epocrates, Medscape, Clinical Pharmacology and Facts & Comparisons are the main alternatives. Prescriber.io lists a Lexidrug personal subscription at $29.99 per month (as of October 2026, prescriber.io), though that is a competitor's figure.

The verdict

If your hospital already licenses it, the AI search is worth trying on interaction and IV compatibility questions, with a pharmacist checking the first batch of answers. If you pay for your own references, price Lexidrug or Epocrates first.